Regulatory Updates
Page 1 • 12 itemsTrack global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
Harmonization of Clinical Trial Regulations: PMDA, TGA & CDSCO Compared
This article compares the clinical trial regulations of PMDA, TGA, and CDSCO, focusing on their impact on drug development and patient safety.
African Medicines Agency Implementation: Transforming Regulatory Harmonization & Market Access
The African Medicines Agency is set to revolutionize regulatory processes, ensuring faster market access for vital medicines across the continent.
NMPA Priority Review Pathway: Accelerating Innovative Drug Approvals in China
The NMPA Priority Review Pathway accelerates the approval of innovative drugs in China, significantly benefiting patients with critical health needs.
NMPA Data Integrity Compliance: What Foreign Pharma Must Know in APAC
Navigating NMPA data integrity compliance is crucial for foreign pharmaceutical companies in APAC. Discover essential guidelines for successful drug registration.
NMPA Data Integrity Requirements: What Foreign Pharma Must Know in APAC
Understanding NMPA data integrity requirements is crucial for foreign pharmaceutical companies seeking to navigate the APAC market effectively.
NMPA Data Integrity Requirements: What Foreign Pharma Must Know in APAC
Understanding NMPA data integrity requirements is essential for foreign pharmaceutical companies aiming to navigate drug registration in the APAC region.
Biosimilar Regulation Japan: Aligning PMDA with EMA and FDA Guidelines
This article examines Japan's biosimilar regulations, focusing on how the PMDA aligns with EMA and FDA guidelines to enhance the approval process for drugs like infliximab.
China NMPA Data Integrity: What Foreign Pharma Must Know for Approval
Understanding China NMPA data integrity is crucial for foreign pharmaceutical companies seeking approval for their drugs in the competitive Chinese market.
PMDA SAKIGAKE Designation: Accelerating Innovative Drug Approvals in Japan
The PMDA SAKIGAKE Designation streamlines the approval process for innovative drugs, such as XYZ for cancer, fostering quicker patient access in Japan.
SAKIGAKE Designation Japan: Accelerating Novel Oncology Drug Approvals
SAKIGAKE Designation in Japan fast-tracks the approval process for innovative oncology drugs, including XYZ-123, aiming to improve patient outcomes in cancer care.
PMDA SAKIGAKE Designation: Transforming Innovative Drug Approvals in Japan
The PMDA SAKIGAKE Designation is revolutionizing the approval process for innovative drugs in Japan, ensuring faster access to essential treatments like XYZ for cancer patients.
SAKIGAKE Designation Japan: What You Need to Know About PMDA's Expedited Pathway
Learn about the SAKIGAKE Designation in Japan, a fast-track pathway by PMDA for innovative drugs, enhancing access for patients with unmet medical needs.